您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > TDO-IN-1
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
TDO-IN-1
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
TDO-IN-1图片
CAS NO:2490672-92-7
包装与价格:
包装价格(元)
100mg电议
250mg电议
500mg电议

产品介绍
TDO-IN-1 是色氨酸 2,3-双加氧酶 (TDO) 的选择性抑制剂 (IC50=0.62 μM),具有口服活性,且对TDO的选择性高于吲哚胺-2,3-双加氧酶 (IDO,IC50>100 μM)。TDO-IN-1 能够逆转肿瘤组织的局部免疫耐受来抑制体内肿瘤生长。
生物活性

TDO-IN-1 is an orally active and selective inhibitor oftryptophan 2,3-dioxygenase(TDO), shows excellent selectivity overindoleamine-2,3-dioxygenase(IDO), with anIC50value of 0.62 μM (IDO). TDO-IN-1 reverse the local immune tolerance of tumor tissue to inhibit tumor growth in vivo[1].

IC50& Target

IC50: 0.62 μM (tryptophan 2,3-dioxygenase, TDO)[1]

体外研究
(In Vitro)

TDO-IN-1 (HT-28) (0-100 μM; 24 h) shows significant tumoricidal effect on different tumor lines, with IC50s of 0.54 μM (HepG2), 5.08 μM (Hepa1-6), 1.34 μM (H22), 37.39 μM (B16), 3.43 μM (MOLM-13), and 7.25 μM (Jurkat), respectively[1].
TDO-IN-1 (0-100 μM; 24 h) exhibits few cytotoxic activity against normal cells (HEK 293 cells) below 10 μM[1].

体内研究
(In Vivo)

TDO-IN-1 (HT-28) (25 mg/kg; p.o.; once daily; 9 d) improve the effect of tumor immunotherapy of CT26 tumor expressing TDO, substantially inhibits the proliferation of CT26 tumors in mice[1].

Animal Model:CT-26 allograft BALB/c mice (6-8 weeks old, female)[1]
Dosage:12.5, 25, and 50 mg/kg
Administration:Oral gavage; once daily; 9 days
Result:Resulted significant reduction in tumor weight and volume in mice, with the tumor volume inhibiton rate of 76.93%.
Reduced the expression of Foxp3 and enhance the expression of CD8 and TNF-α in tumor tissue to increase the immune response of tumor-bearing mice.
分子量

350.30

Formula

C16H13F3N4O2

CAS 号

2490672-92-7

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.